This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

This study has been completed.
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A. Identifier:
First received: August 23, 2012
Last updated: March 28, 2017
Last verified: March 2017
Phase IIa study in COPD patients aimed to evaluate the safety, tolerability ,pharmacodynamics (effect on biological markers of inflammation in induced sputum and in blood, and on pulmonary function) and on pharmacokinetics of CHF 6001 (a PDE4 inhibitor) after 28-days of daily inhaled dosing.

Condition Intervention Phase
COPD Drug: CHF6001 DPI Drug: Roflumilast Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Double-dummy, Placebo and Active-controlled, Three-way Crossover Study to Evaluate the Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI (1200 µg Daily) in Subjects With COPD

Further study details as provided by Chiesi Farmaceutici S.p.A.:

Primary Outcome Measures:
  • Adverse events, adverse drug reactions, serious adverse. [ Time Frame: After 28 days of treatment ]
    The number and percentage of subjects experiencing AEs, ADRs, serious AEs and AEs leading to study withdrawal.

  • Vital signs [ Time Frame: After 28 days of treatment ]
  • 12-lead ECG parameters [ Time Frame: After 28 days of treatment ]

Secondary Outcome Measures:
  • Pharmacokinetics of CHF 6001 and its metabolites [ Time Frame: After 28 days of treatment ]
  • Induction of sputum [ Time Frame: After 28 days of treatment ]
    Biomarkers of inflammation

  • Baseline Dyspnea Index and Transition Dyspnea Index Questionnaire [ Time Frame: After 28 days of treatment ]
  • Lung function measurements [ Time Frame: After 28 days of treatment ]

Enrollment: 55
Study Start Date: October 2012
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CHF6001
CHF6001 DPI (Dry Powder Inhaler) once daily
Drug: CHF6001 DPI
Active Comparator: Roflumilast
Roflumilast, tablet, once daily
Drug: Roflumilast
Placebo Comparator: placebo
Drug: Placebo


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written informed consent obtained prior to any study-related procedures.
  2. Male or female aged between 40 and 70 years inclusive.
  3. Current or past smoker of at least 10 pack/years
  4. BMI in the range of 18-35 Kg/m2
  5. GOLD Stage 2 and 3 COPD subjects
  6. A history of chronic bronchitis defined as chronic cough and sputum production
  7. At screening, subjects must be able to produce an adequate induced sputum sample
  8. Female subjects: post-menopausal women having at least 12 months of natural (spontaneous) amenorrhea, or women of childbearing potential using two acceptable methods of contraception for the duration of the study and for the following three months

Exclusion criteria:

  1. Female subjects: pregnant or lactating women
  2. Past or current history of asthma
  3. History of clinically significant hypotensive episodes
  4. History or symptoms of significant cardiovascular disease
  5. History or symptoms of significant neurological disease
  6. Unstable concurrent disease
  7. An abnormal and clinically significant 12-lead ECG
  8. Clinically relevant abnormal laboratory values
  9. Use of oral or systemic corticosteroids oral and/or nebulised Beta2 agonists and/or antibiotics within 6 weeks preceding the screening visit
  10. Moderate or severe hepatic impairment (Child-Pugh B or C)
  11. Intolerance/hypersensitivity or any contraindication to treatment with roflumilast, tiotropium bromide or salbutamol or any of the excipients contained in the formulations used in the study
  12. Chronic use of any other medication for treatment of lung disease like xanthines, antileukotrienes, systemic and inhaled corticosteroids, long acting beta2- agonists, roflumilast (other than the study drug) and cromoglycates
  13. Long term (at least 12 hours daily) use of oxygen therapy for chronic hypoxemia.
  14. Having received an investigational medicinal drug within 30 days prior to study entry
  15. Blood draws of 250 mL or more within 45 days prior to enrolment into the study.
  16. Known respiratory disorders other than COPD.
  17. History of alcohol dependency, or substance abuse
  18. Inability to comply with the study Protocol for any other reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01730404

Belfast, Ireland
United Kingdom
Parexel, early phases
Harrow, United Kingdom
Medicines Evaluation Unit Ltd
Manchester, United Kingdom
Freeman Hospital
Newcastle, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
Principal Investigator: Dave Singh, MD MEU
Principal Investigator: Anthony DeSoyza, MD Freeman Health System
Principal Investigator: Stephen Smith, MD Celerion
Principal Investigator: Tim Harrison, MD Nottingham University Hospitals NHS Trust
Principal Investigator: Muna Albayaty, MD Parexel, early phases
  More Information

Additional Information:
Responsible Party: Chiesi Farmaceutici S.p.A. Identifier: NCT01730404     History of Changes
Other Study ID Numbers: CCD-1201-PR-0079
Study First Received: August 23, 2012
Last Updated: March 28, 2017 processed this record on June 22, 2017